Difference between revisions of "Part:BBa K1228006"

(→‎Reference)
Line 2: Line 2:
 
<partinfo>BBa_K1228006 short</partinfo>
 
<partinfo>BBa_K1228006 short</partinfo>
  
−
Lf (loctoferrin) is located in many key body fluids , e.g., milk, tears, saliva and other secretions, and in white blood cells ,it has become clear that it is an important part of mammalian defence mechanisms, with a wide range of protective functions.25 amino acid residues is from Lf but has a strong bactericidal, bacteriostatic ability, and the antimicrobial activity than natural LF.We add T1 terminator and Constitutive promoter veg on the 25aa to make it can  work regularly.
+
This generator combines of BBa_K541503(https://parts.igem.org/Part:BBa_K541503) and BBa_K1228005(https://parts.igem.org/Part:BBa_K1228005). The generator can secrete 25 aminacid peptide that is a part of Lactoferrin in ''B.subtilis''. It has a broad anti-bacterial range and strong anti-bacterial activity.
  
  

Revision as of 09:18, 27 September 2013

25aa with T1 terminator and Constitutive promoter veg

This generator combines of BBa_K541503(https://parts.igem.org/Part:BBa_K541503) and BBa_K1228005(https://parts.igem.org/Part:BBa_K1228005). The generator can secrete 25 aminacid peptide that is a part of Lactoferrin in B.subtilis. It has a broad anti-bacterial range and strong anti-bacterial activity.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Reference

1.BellamyW,TakaseM,Yamauchi K,et al. Identification of the bactericidal domainof lactoferrin[J]. BiochimicaetBiophysicaActa,1992,1121( 1/2):130-136. 2.EliassenLT,Berge G,SveinbjornssonB,et al. Evidenceforadirect antitumormechanismof actionof Bovinel actoferricin[J].AnticancerResearch,2002,22(5):2703－2710. 3.Wakabayashi H,TakaseM,TomitaM. Lactoferricin derived from milk protein lactoferrin[J]. Current Pharmaceutical Design,2003,9(16):1277－1287.